References 1. Field MJ, Cassel CK. Approaching Death: Improving Care at the End of Life. Washington DC: Institute of Medicine; 1997. 2. Institute of Medicine. Dying in America: Improving quality and honoring individual preferences near the end of life. Washington, DC: The National Academies Press; 2015. 3. Kass-Bartelmes BL, Huges R, Rutherford MK. Advance Care Planning: Preferences for Care at the End of Life. Rockville MD: Agency for Healthcare Research and Quality; 2003. 4. Bradley EH, Rizzo JA. Public information and private search: evaluating the Patient Self-Determination Act. J Health Polit Policy Law. 1999;24(2):239-273. 5. Yadav KN, Gabler NB, Cooney E, et al. Approximately One In Three US Adults Completes Any Type Of Advance Directive For End-Of-Life Care. Health Aff (Millwood). 2017;36(7):1244-1251. 6. Teno JM, Licks S, Lynn J, et al. Do advance directives provide instructions that direct care? SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. J Am Geriatr Soc. 1997;45(4):508-512. 7. Danis M, Mutran E, Garrett JM, et al. A prospective study of the impact of patient preferences on life- sustaining treatment and hospital cost. Crit Care Med. 1996;24(11):1811-1817. 8. Centers for Disease Control and Prevention. Deaths: Final Data for 2017. https://www.cdc.gov/ nchs/fastats/deaths.htm. Accessed April 7, 2020. 9. Emanuel LL, Barry MJ, Stoeckle JD, Ettelson LM, Emanuel EJ. Advance directives for medical care--a case for greater use. N Engl J Med. 1991;324(13):889-895. 10. Smucker WD, Ditto PH, Moore KA, Druley JA, Danks JH, Townsend A. Elderly outpatients respond favorably to a physician-initiated advance directive discussion. J Am Board Fam Pract. 1993;6(5):473- 482. 11. Moore KA, Danks JH, Ditto PH, Druley JA, Townsend A, Smucker WD. Elderly outpatients’ understanding of a physician-initiated advance directive discussion. Arch Fam Med. 1994;3(12):1057-1063. 12. Fischer GS, Tulsky JA, Rose MR, Siminoff LA, Arnold RM. Patient knowledge and physician predictions of treatment preferences after discussion of advance directives. J Gen Intern Med. 1998;13(7):447-454. 13. Lynn J, Arkes HR, Stevens M, et al. Rethinking fundamental assumptions: SUPPORT’s implications for future reform. Study to Understand Prognoses and Preferences and Risks of Treatment. J Am Geriatr Soc. 2000;48(S1):S214-221. 14. Danis M, Garrett J, Harris R, Patrick DL. Stability of choices about life-sustaining treatments. Ann Intern Med. 1994;120(7):567-573. 15. Rosenfeld KE, Wenger NS, Phillips RS, et al. Factors associated with change in resuscitation preference of seriously ill patients. The SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Arch Intern Med. 1996;156(14):1558-1564. 16. Fetters MD, Churchill L, Danis M. Conflict resolution at the end of life. Crit Care Med. 2001;29(5):921- 925. 17. Ngo-Metzger Q, August KJ, Srinivasan M, Liao S, Meyskens FL, Jr. End-of-Life care: guidelines for patient-centered communication. Am Fam Physician. 2008;77(2):167-174. 18. Quill TE. Perspectives on care at the close of life. Initiating end-of-life discussions with seriously ill patients: addressing the “elephant in the room”. JAMA. 2000;284(19):2502-2507.
19. Fishman SM. Responsible Opioid Prescribing: A Clinician’s Guide, 2nd Ed. Washington, DC: Waterford Life Sciences; 2012. 20. Gramelspacher GP, Zhou XH, Hanna MP, Tierney WM. Preferences of physicians and their patients for end-of-life care. J Gen Intern Med. 1997;12(6):346- 351. 21. Cohen-Mansfield J, Droge JA, Billig N. Factors influencing hospital patients’ preferences in the utilization of life-sustaining treatments. Gerontologist. 1992;32(1):89-95. 22. Atul Gawande. Being Mortal. New York, NY: Penquin Books; 2014. 23. Berkey FJ, Wiedemer JP, Vithalani ND. Delivering Bad or Life-Altering News. Am Fam Physician. 2018;98(2):99-104. 24. Baile WF, Buckman R, Lenzi R, Glober G, Beale EA, Kudelka AP. SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer. Oncologist. 2000;5(4):302-311. 25. Searight HR, Gafford J. Cultural diversity at the end of life: issues and guidelines for family physicians. Am Fam Physician. 2005;71(3):515-522. 26. Blackhall LJ, Murphy ST, Frank G, Michel V, Azen S. Ethnicity and attitudes toward patient autonomy. JAMA. 1995;274(10):820-825. 27. Candib LM. Truth telling and advance planning at the end of life: problems with autonomy in a multicultural world. Fam Syst Health. 2002;20:213- 228. 28. Miller SC, Mor V. The emergence of Medicare hospice care in US nursing homes. Palliat Med. 2001;15(6):471-480. 29. National Hospice and Palliative Care Organization. NHPCO Facts and Figures 2018 Edition. Alexandria VA. 2018. 30. Weckmann MT. The role of the family physician in the referral and management of hospice patients. Am Fam Physician. 2008;77(6):807-812. 31. Na Y. Doctors can’t do everything and save everyone. New York Times. May 5, 2020(Section A):27. 32. Crooks V, Waller S, Smith T, Hahn TJ. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991;46(4):M139-144. 33. The National Hospice Organization. Medical guidelines for determining prognosis in selected non-cancer diseases. . Hosp J. 1996;11(2):47-63. 34. Anderson F, Downing GM, Hill J, Casorso L, Lerch N. Palliative performance scale (PPS): a new tool. J Palliat Care. 1996;12(1):5-11. 35. Maltoni M, Nanni O, Pirovano M, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage. 1999;17(4):240-247. 36. Albert RH. End-of-Life Care: Managing Common Symptoms. Am Fam Physician. 2017;95(6):356- 361. 37. Byock I. Dying Well: The Prospect for Growth at the End of Life. New York, NY: Riverhead Books; 1997. 38. Patrick DL, Pearlman RA, Starks HE, Cain KC, Cole WG, Uhlmann RF. Validation of preferences for life- sustaining treatment: implications for advance care planning. Ann Intern Med. 1997;127(7):509-517. 39. Forrow L, Smith HS. Pain Management in End of Life: Palliative Care. In: Warfield CA, Bajawa ZH, eds. Principles & Practice of Pain Medicine, 2nd Ed. New York, NY: McGraw-Hill; 2004. 40. Abrahm JL. A Physician’s Guide to Pain and Symptom Management in Cancer Patients. Baltimore, MD: Johns Hopkins University Press; 2005.
41. Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin. 2011;61(3):157-182. 42. Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage. 2000;20(4):246- 252. 43. Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol. 1983;13(2):180-185. 44. Hawley PH, Byeon JJ. A comparison of sennosides- based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med. 2008;11(4):575-581. 45. Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35(5):458-468. 46. Bruera E, Driver L, Barnes EA, et al. Patient- controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol. 2003;21(23):4439- 4443. 47. Morita T, Tsunoda J, Inoue S, Chihara S. Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manage. 2001;21(4):282-289. 48. Sykes N, Thorns A. The use of opioids and sedatives at the end of life. Lancet Oncol. 2003;4(5):312- 318. 49. Berlinger N, Jennings B, Wolf SM. The Hastings Center Guidelines for Decisions on Life-Sustaining Treatment and Care Near the End of Life. New York NY: The Hastings Center; 2013. 50. McNicol E, Strassels SA, Goudas L, Lau J, Carr DB. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev. 2005(1):CD005180. 51. Harris G. FDA Plans New Limits on Prescription Painkillers. New York Times. January 13 2011. 52. Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007;42:3-27. 53. Schlansky B, Hwang JH. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. J Gastroenterol. 2009;44 Suppl 19:44-52. 54. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older P. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331-1346. 55. Swarm R, Abernethy AP, Anghelescu DL, et al. Adult cancer pain. J Natl Compr Canc Netw. 2010;8(9):1046-1086. 56. Portenoy RK, Ahmed E, Keilson Y. Cancer pain management: Adjuvant analgesics. https://www. uptodate.com/contents/cancer-pain-management- adjuvant-analgesics-coanalgesics. Accessed January 21 2020. 57. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150(3):573-581. 58. Durand JP, Goldwasser F. Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. Anticancer Drugs. 2002;13(7):777-780. 59. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113-121.
40
Powered by FlippingBook